FrancophonIA/ELRC3.0 huggingface dataset:
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) YENTREVE EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) YENTREVE Povzetek EPAR za javnost
English: Treatment with Yentreve should not be started in patients with uncontrolled high blood pressure, because of a risk of hypertensive crisis (sudden, dangerously high blood pressure).
Slovenian: Zdravljenje z zdravilom Yentreve se ne sme uvesti pri bolnicah z nenadzorovanim visokim krvnim tlakom zaradi tveganja za hipertenzivno krizo (nenadni, nevaren visok krvni tlak).
English: By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between these nerve cells, increasing the level of communication between the cells.
Slovenian: Duloksetin s tem, ko prepreči njihovo ponovno vezavo, zviša količino teh živčnih prenašalcev v prostorih med živčnimi celicami, s čimer se poveča stopnja sporazumevanja med celicami.
English: The main measures of effectiveness were incontinence episode frequency (IEF, the number of episodes of incontinence per week) recorded in patient diaries and the patients' scores on an incontinence-specific quality-of-life questionnaire (I-QOL).
Slovenian: Glavni merili učinkovitosti sta bili pogostnost inkontinenčnih epizod (IEF, tj. število inkontinenčnih epizod na teden), razvidno iz dnevnikov zdravljenja ter bolnikovega števila točk po vprašalniku o kakovosti življenja, specifičnem za inkontinenco (I-QOL).
English: Yentreve is a medicine containing the active substance duloxetine.
Slovenian: Yentreve je zdravilo, ki vsebuje zdravilno učinkovino duloksetin.
English: The most common side effects with Yentreve (seen in more than 1 patient in 10) are nausea, dry mouth, constipation and fatigue (tiredness).
Slovenian: Najpogostejši neželeni učinki zdravila Yentreve (opaženi pri več kot 1 bolnici od 10) so slabost, suha usta, zaprtje in utrujenost.
English: Yentreve is used to treat moderate to severe stress urinary incontinence (SUI) in women.
Slovenian: Zdravilo Yentreve se uporablja za zdravljenje zmerne do hude stresne urinske inkontinence (SUI) pri ženskah.
English: What is the risk associated with Yentreve?
Slovenian: Kakšna tveganja so povezana z zdravilom Yentreve?
English: In all four studies, the patients treated with Yentreve had fewer episodes of incontinence after 12 weeks, with about four or five fewer episodes of incontinence per week, in comparison with the number before the study.
Slovenian: V vseh štirih študijah so imele bolnice, ki so prejemale zdravilo Yentreve, manj inkontinenčnih epizod po 12 tednih, in sicer približno štiri ali pet inkontinenčnih epizod manj na teden v primerjavi z obdobjem pred študijo.
English: Yentreve should not be used with monoamine oxidase inhibitors (a group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic).
Slovenian: Zdravilo Yentreve se ne sme uporabljati z zaviralci monoamin-oksidaze (skupino zdravil proti depresiji), fluvoksaminom (drugim zdravilom proti depresiji) ali ciprofloksacinom in enoksacinom (vrsti antibiotika).
English: Why has Yentreve been approved?
Slovenian: Zakaj je bilo zdravilo Yentreve odobreno?
English: How duloxetine works in SUI is not clear but it is thought that, by increasing the levels of 5-hydroxytryptamine and noradrenaline at the level of the nerves that control the muscle of the urethra (the tube that leads from the bladder to outside), duloxetine causes a stronger closure of the urethra during urine storage.
Slovenian: Način delovanja zdravila pri stresni urinski inkontinenci ni jasen, vendar se domneva, da duloksetin s povečevanjem ravni 5-hidroksitriptamina in noradrenalina na raven v živcih, ki nadzorujejo mišice sečnice (izvodilo iz sečnega mehurja navzven), okrepi stisk mišic zapiralk sečnice med shranjevanjem urina.
English: It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Slovenian: Deluje tako, da živčnim prenašalcem 5-hidroksitriptamina (imenovanim tudi serotonin) in noradrenalinu preprečuje ponovno vezavo na živčne celice v možganih in hrbtenjači.
English: Yentreve should not be used in people who may be hypersensitive (allergic) to duloxetine or any of the other ingredients.
Slovenian: Zdravila Yentreve ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) duloksetin ali katero koli drugo sestavino zdravila.
English: Yentreve was more effective than placebo only in patients who had more than 14 incontinence episodes per week (moderate to severe SUI) at the start of the study.
Slovenian: Zdravilo Yentreve je bilo učinkovitejše od placeba le pri bolnicah, ki so imele na začetku študije več kot 14 inkontinenčnih epizod na teden (zmerna do huda SUI).
English: For the full list of all side effects reported with Yentreve, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Yentreve, glejte navodilo za uporabo.
English: The four main studies involved 1,913 women and lasted 12 weeks, comparing Yentreve (mostly as 40 mg twice daily) with placebo (a dummy treatment).
Slovenian: V štiri glavne študije, ki so trajale 12 tednov, je bilo vključenih 1913 žensk, v njih pa so primerjali zdravilo Yentreve (večinoma v odmerku 40 mg dvakrat na dan) s placebom (zdravilom brez zdravilne učinkovine).
English: The I-QOL questionnaire scores were also improved in the Yentreve group compared with the placebo group.
Slovenian: V skupini bolnic, ki so prejemale zdravilo Yentreve, se je izboljšal tudi rezultat po vprašalniku I-QOL v primerjavi s skupino bolnic, ki so prejemale placebo.
English: The active substance in Yentreve, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor (SNRI).
Slovenian: Zdravilna učinkovina zdravila Yentreve, duloksetin, je zaviralec ponovnega prevzema serotonina in noradrenalina (SNRI).
English: By closing the urethra more powerfully, Yentreve prevents the unwanted loss of urine during physical stress such as coughing or laughing.
Slovenian: Zdravilo Yentreve z močnejšim stiskom mišic zapiralk sečnice preprečuje neželeno uhajanje urina med telesnim naporom, npr. kašljanjem ali smejanjem.
English: The IEF decreased by 52% in the Yentreve group, compared with a decrease of 33% in the placebo-treated group.
Slovenian: Pogostnost inkontinenčnih epizod se je v skupini bolnic, ki so prejemale zdravilo Yentreve, zmanjšala za 52 %, v primerjavi s skupino bolnic, ki so prejemale placebo, pa se je zmanjšala za 33 %.
English: The full EPAR for Yentreve is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Yentreve je na voljo tukaj.
English: Yentreve should not be used in patients with certain types of liver disease or with severe kidney disease.
Slovenian: Zdravilo Yentreve se ne sme uporabljati pri osebah z določenimi vrstami obolenj jeter ali hudim obolenjem ledvic.
English: SUI is accidental leaks of urine during physical exertion or when coughing, laughing, sneezing, lifting or exercising.
Slovenian: Huda stresna urinska inkontinenca je nenamerno uhajanje urina med telesnim naporom, kašljanjem, smejanjem, kihanjem, dviganjem ali telesno vadbo.
English: Yentreve has been studied in a total of 2,850 women with SUI.
Slovenian: Zdravilo Yentreve so preučevali na skupno 2850 ženskah s stresno urinsko inkontinenco.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Yentreve's benefits are greater than its risks for the treatment of moderate to severe SUI.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Yentreve pri zdravljenju zmerne do hude stresne urinske inkontinence večje od z njim povezanih tveganj.
English: How is Yentreve used?
Slovenian: Kako se zdravilo Yentreve uporablja?
English: Some patients may benefit from starting treatment at a dose of 20 mg twice a day for two weeks before increasing to 40 mg twice a day, to reduce nausea (feeling sick) and dizziness.
Slovenian: Priporočeni odmerek zdravila Yentreve je 40 mg dvakrat na dan. Za zmanjšanje slabosti in omotice lahko nekaterim bolnicam koristi začetno zdravljenje z odmerkom 20 mg dvakrat na dan v trajanju dveh tednov, čemur sledi zvišanje odmerka na 40 mg dvakrat na dan.
English: What is Yentreve used for?
Slovenian: Za kaj se zdravilo Yentreve uporablja?
English: Combining Yentreve with pelvic floor muscle training may provide additional benefit.
Slovenian: Dodatne koristi lahko prinese kombiniranje jemanja zdravila Yentreve s programom treninga mišic medeničnega dna.
English: How does Yentreve work?
Slovenian: Kako zdravilo Yentreve deluje?
English: How has Yentreve been studied?
Slovenian: Kako je bilo zdravilo Yentreve raziskano?
English: What is Yentreve?
Slovenian: Kaj je zdravilo Yentreve?
English: Some of these serious side effects may lead to death.
Slovenian: Nekateri od teh resnih neželenih učinkov lahko vodijo v smrt.
English: • Your doctor will tell you how many tablets to take each time.
Slovenian: • Vaš zdravnik vam bo povedal, koliko tablet vzeti vsakokrat.
English: ANNEX IV CONCLUSIONS ON THE REQUEST FOR ONE-YEAR MARKETING PROTECTION PRESENTED BY THE EUROPEAN MEDICINES AGENCY
Slovenian: PRILOGA IV SKLEPNE UGOTOVITVE O ZAHTEVKU ZA ENOLETNO TRŽNO ZAŠČITO, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 April 2016
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 25. april 2016
English: • It is used when other treatments have not worked - or when other treatments are not suitable for you.
Slovenian: • Uporablja se potem, ko druga zdravila niso pomagala, ali v primeru, da druga zdravila za vas niso primerna.
English: • changes in the menstrual cycle
Slovenian: • spremembe menstrualnega cikla
English: Efficacy and safety data in patients over 75 years old is limited.
Slovenian: Podatkov o učinkovitosti in varnosti pri bolnikih, starejših od 75 let, je malo.
English: • Swallow the tablets whole with a glass of water.
Slovenian: • Tablete pogoltnite cele s kozarcem vode.
English: System Organ Class (MedDRA)a
Slovenian: Razred organskega sistema (MedDRA)a
English: • It is used when the cancer has spread to other parts of the body.
Slovenian: • Uporabljamo ga za zdravljenje raka, ki se je razširil na druge dele telesa.
English: Therefore, Lonsurf should be treated as a potential carcinogen.
Slovenian: Zdravilo Lonsurf je zato treba obravnavati kot potencialen karcinogen.
English: • pain, including pain from the cancer
Slovenian: • bolečina, vključno z bolečino zaradi raka
English: • one-year marketing protection
Slovenian: • enoletni tržni zaščiti
English: Patients with severe renal impairment were not enrolled in the study.
Slovenian: Bolniki s hudo ledvično okvaro v študijo niso bili vključeni.
English: You start a new cycle every 4 weeks.
Slovenian: Z novim ciklom zdravljenja boste začeli vsake 4 tedne.
English: Therefore, caution is required when using medicinal products that interact with these transporters.
Slovenian: Zato je pri uporabi zdravil, ki vstopajo v interakcije s temi prenašalci, potrebna previdnost.
English: • Your doctor will decide the right dose for you - the dose depends on your weight and height.
Slovenian: • Vaš zdravnik bo odločil, kateri je pravi odmerek za vas - odmerek je odvisen od vaše telesne mase in višine.
English: • Take this medicine by mouth.
Slovenian: • Zdravilo jemljite skozi usta.
English: If you become pregnant, you and your doctor will have to decide if the benefits of Lonsurf are greater than the risk of harm to the baby.
Slovenian: Če zanosite, se boste morali vi in vaš zdravnik odločiti, ali so koristi zdravila Lonsurf večje od tveganja za škodljive učinke na vašega otroka.
English: Read all of this leaflet carefully before you start taking this medicine - because it contains important information for you.
Slovenian: Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
English: The dosage must not exceed 80 mg/dose.
Slovenian: Odmerjanje ne sme preseči 80 mg/odmerek.
English: Tumor assessments, according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, were performed by the investigator/local radiologist every 8 weeks.
Slovenian: Ocene tumorja je v skladu z merili za ocenjevanje odziva pri solidnih tumorjih (RECIST - Response Evaluation Criteria in Solid Tumors), različica 1.1, izvajal raziskovalec/ lokalni radiolog vsakih 8 tednov.
English: Your doctor may prescribe both strengths for your prescribed dose.
Slovenian: Vaš zdravnik vam bo za vaš predpisani odmerek lahko predpisal obe jakosti.
English: DATE OF REVISION OF THE TEXT MM/YYYY
Slovenian: DATUM ZADNJE REVIZIJE BESEDILA MM/LLLL
English: • problem with sleeping or falling asleep
Slovenian: • težave s spanjem in uspavanjem.
English: Survival Probability (%)
Slovenian: Verjetnost preživetja (%)
English: See Section 4.8 for how to report adverse reactions.
Slovenian: Glejte poglavje 4.8, kako poročati o neželenih učinkih.
English: • Do not increase dose after it has been reduced.
Slovenian: • Ne povečajte odmerka, potem ko ste ga že zmanjšali.
English: • if you are allergic to trifluridine or tipiracil or any of the other ingredients of this medicine (listed in section 6).
Slovenian: • Če ste alergični na trifluridin ali tipiracil ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: This includes medicines obtained without a prescription and herbal medicines.
Slovenian: To vključuje tudi zdravila, ki ste jih dobili brez recepta, ter zdravila rastlinskega izvora.
English: 92284 Suresnes Cedex France
Slovenian: 92284 Suresnes cedex
English: • You will take a dose 2 times a day.
Slovenian: • Odmerek boste vzeli 2-krat na dan.
English: The CHMP reviewed the data submitted by the marketing authorisation holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je pregledal podatke, ki jih je predložil imetnik dovoljenja za promet z zdravilom, pri čemer je upošteval določbe člena 14(11) Uredbe (ES) št. 726/2004, in meni, da nova terapevtska indikacija prinaša pomembno klinično korist v primerjavi z obstoječimi terapijami, kot je podrobneje razloženo v evropskem javnem poročilu o oceni zdravila.
English: In vitro interaction studies
Slovenian: Študije medsebojnega delovanja in vitro
English: Therefore, women using hormonal contraceptive must also use a barrier contraceptive method.
Slovenian: Ženske, ki uporabljajo hormonske kontraceptive, morajo zato uporabiti tudi pregradno metodo kontracepcije.
English: Take your pack(s) of medicine with you.
Slovenian: S seboj vzemite škatlo(e) zdravil(a).
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Slovenian: Zahteve glede predložitve rednega posodobljenega PSUR za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
English: The tests are needed because Lonsurf can sometimes affect your blood cells.
Slovenian: Preiskave so potrebne, ker lahko zdravilo Lonsurf včasih vpliva na krvne celice.
English: The median number of prior lines of therapy for metastatic disease was 3.
Slovenian: Mediana števila predhodnih linij zdravljenja metastatske bolezni je bila 3.
English: • Anaemia (very common).
Slovenian: • anemija (zelo pogosti).
English: Many of the side effects are shown in laboratory tests - for example those affecting your blood cells.
Slovenian: Mnogi neželeni učinki so razvidni iz laboratorijskih preiskav - na primer tisti, ki vplivajo na krvne celice.
English: • changes in urine test, blood in urine
Slovenian: • spremembe v preiskavah urina, kri v urinu
English: Treatment may lead to the following side effects (see section 4):
Slovenian: Zdravljenje lahko povzroči naslednje neželene učinke (glejte poglavje 4):
English: • Vomiting (very common) and diarrhoea (very common), which may lead to a dehydration if severe or persistent.
Slovenian: • bruhanje (zelo pogosti) in diareja (zelo pogosti), ki lahko vodita v dehidracijo, če sta hudi ali dolgotrajni;
English: • Week 3 - No medicine
Slovenian: • 3. teden - Brez zdravila.
English: • protein in your urine
Slovenian: • beljakovine v urinu
English: Women of childbearing potential / Contraception in males and females
Slovenian: Ženske v rodni dobi/kontracepcija pri moških in ženskah
English: The tablets must be taken with a glass of water within 1 hour after completion of the morning and evening meals.
Slovenian: Tablete mora bolnik vzeti s kozarcem vode v 1 uri po koncu jutranjega in večernega obroka.
English: • low levels of albumin or total protein in the blood
Slovenian: • nizke vrednosti albumina ali celotnih proteinov v krvi
English: • Tipiracil stops the trifluridine from being broken down by the body, helping trifluridine to work longer.
Slovenian: • Tipiracil preprečuje razgradnjo trifluridina v telesu in mu tako pomaga, da deluje dlje časa.
English: • blood test result indicating inflammation (C-Reactive Protein increased)
Slovenian: • izvid krvne preiskave, ki kaže na vnetje (zvišana vrednost C-reaktivnega proteina)
English: Frequency groups are defined by the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); and uncommon (≥1/1,000 to < 1/100).
Slovenian: Skupine pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti ( ≥ 1/100 do < 1/10) in občasni (≥ 1/1.000 do
English: The adverse drug reactions reported in association with overdoses were consistent with the established safety profile.
Slovenian: Neželeni učinki, o katerih so poročali v povezavi s prevelikim odmerjanjem, so bili v skladu z uveljavljenim varnostnim profilom.
English: b. Fatal cases have been reported.
Slovenian: b Poročani so bili smrtni primeri.
English: How to take You will take Lonsurf for 10 days during the first 2 weeks, and then have 2 weeks off.
Slovenian: Kako jemati zdravilo Zdravilo Lonsurf boste jemali 10 dni v prvih 2 tednih, nato boste imeli 2 tedna premora.
English: Age, gender and race
Slovenian: Starost, spol in etnična pripadnost
English: • changes in your heart trace (ECG - electrocardiogram)
Slovenian: • spremembe v zapisu srčnega ritma (EKG - elektrokardiogram)
English: The target organs identified were the lymphatic and haematopoietic systems and the gastrointestinal tract.
Slovenian: Ugotovljeni ciljni organi so bili limfatični in hematopoetski sistem ter gastrointestinalni trakt.
English: Lonsurf should not be used during pregnancy unless the clinical condition of the woman requires treatment with Lonsurf.
Slovenian: Zdravila Lonsurf ne smete uporabljati med nosečnostjo, razen če klinično stanje nosečnice zahteva zdravljenje z zdravilom Lonsurf.
English: Do not take Lonsurf if the above applies to you.
Slovenian: Ne jemljite zdravila Lonsurf, če navedeno velja za vas.
English: Do not use this medicine after the expiry date which is stated on the outer carton or blister tray after “EXP.” The expiry date refers to the last day of that month.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: • increased bilirubin in your blood - can cause yellowing of skin or eyes
Slovenian: • zvišanje vrednosti bilirubina v krvi - kar lahko povzroči rumeno obarvanje kože ali oči
English: Tell your doctor immediately if you notice any of the following serious side effects (many of the side effects are shown in laboratory tests - for example those affecting your blood cells):
Slovenian: Resni neželeni učinki Če opazite katerega koli od naslednjih neželenih učinkov, takoj obvestite svojega zdravnika (veliko neželenih učinkov se kaže v laboratorijskih izvidih - na primer tisti, ki vplivajo na krvne celice):
English: The highest dose of Lonsurf administered in clinical trials was 180 mg/m2 per day.
Slovenian: Največji odmerek zdravila Lonsurf v kliničnih študijah je bil 180 mg/m2 na dan.
English: For low albumin values ranging from 2.2 to 3.5 g/dL, the corresponding clearance values range from 4.2 to 3.1 L/h.
Slovenian: Pri nizkih vrednostih albumina od 2,2 do 3,5 g/dl, so bile ustrezne vrednosti očistka od 4,2 do 3,1 l/h.
English: However, the incidence of serious, severe AEs and AEs leading to dose modification tends to increase with advancing levels of renal impairment.
Slovenian: Kakor koli incidenca resnih, hudih AEs in AEs, ki so vodili v spremembo odmerka, se povečuje z napredujočo stopnjo ledvične okvare.
English: • a reduced number of red blood cells (anaemia)
Slovenian: • zmanjšano število rdečih krvnih celic (anemija);
English: In RECOURSE and TAGS studies, 9.4% and 17.3% of patients in the Lonsurf group respectively received G-CSF mainly for therapeutic use.
Slovenian: V študijah RECOURSE in TAGS je 9,4 % in 17,3 % bolnikov v skupini, zdravljeni z zdravilom Lonsurf, predvsem v terapevtske namene prejelo G-CSF.
English: Also some other medicines can affect the way Lonsurf works.
Slovenian: Prav tako lahko druga zdravila vplivajo na delovanje zdravila Lonsurf.
English: • Interrupt dosing until toxicity resolves to Grade 1 or baseline.
Slovenian: • Prekinite odmerjanje, dokler se stopnja toksičnosti ne zniža na 1 ali izhodiščno stopnjo.
English: Primary cancer was gastric (71.0%) or gastroesophageal junction cancer (28.6%) or both (0.4%).
Slovenian: Primarni rak je bil rak želodca (71,0 %) ali rak gastroezofagealnega prehoda (28,6 %) ali oba (0,4 %).
English: Lonsurf on overall survival was similar in patients <65 years and ≥65 years of age.
Slovenian: Učinek zdravila Lonsurf na podaljšanje celokupnega preživetja je bil pri bolnikih < 65 let in bolnikih ≥ 65 let podoben.
English: Other medicines and Lonsurf
Slovenian: Druga zdravila in zdravilo Lonsurf
English: Caution is required when using medicinal products that are human thymidine kinase substrates, e.g., zidovudine.
Slovenian: Previdnost je potrebna ob uporabi zdravil, ki so substrati humane timidin-kinaze, npr. zidovudina.
English: Each pack contains 20, 40 or 60 film-coated tablets.
Slovenian: Eno pakiranje vsebuje 20, 40 ali 60 filmsko obloženih tablet.
English: Aluminium/Aluminium blister with laminated desiccant (Calcium oxide) containing 10 tablets.
Slovenian: Aluminij/aluminij pretisni omoti z laminiranim sušilnim sredstvom (kalcijev oksid), ki vsebujejo 10 tablet.
English: The primary site of disease was colon (62%) or rectum (38%).
Slovenian: Primarno mesto bolezni je bilo debelo črevo (62 %) ali rektum (38 %).
English: What Lonsurf is and what it is used for
Slovenian: Kaj je zdravilo Lonsurf in za kaj ga uporabljamo
English: ≥ 75 × 109/L a Resumption criteria applied to the start of the next cycle for all patients regardless of whether or not the interruption criteria were met.
Slovenian:  75  109/l a Kriterija za ponovno uvedbo odmerka na začetku naslednjega cikla se nanašata na vse bolnike ne glede na to, ali so bili izpolnjeni kriteriji za prekinitev zdravljenja.
English: Lonsurf may harm your unborn baby.
Slovenian: Zdravilo Lonsurf lahko škoduje nerojenemu otroku.
English: Total daily dose (mg)
Slovenian: Celotni dnevni odmerek (mg)